Help us: Donate
Follow us on:
×

Menu

Back

Tag: BIOAGE

BioAge logo
BioAge Labs is developing a class of compounds that have been shown to inhibit the NLRP3 protein, which has been linked to all-cause mortality, in mouse models and human cells. These compounds can be taken orally and cross the blood-brain barrier. The full press release is included here. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”,...
BioAge logo
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Here is the company's full press release. RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to...
Champions of Coronavirus
A research paper that has just been peer reviewed and published in Nature has described how disrupting an immune pathway that is upregulated in aging decreases the lethality of COVID-19 in a mouse model. Mice with COVID-19 As the researchers explain, normal mice do not use the same angiotensin converting enzyme 2 (ACE2) as humans,...
BioAge logo
BioAge Labs is off to a fast start in 2021, with two drugs in its pipeline now undergoing clinical trials and a third planned to start in the near future. BioAge Labs Building momentum After a $90 million Series C funding round closed late last year, BioAge has moved quickly to start the new year....
BioAge logo
BioAge, in a recent press release, has announced the start of its phase 2a clinical trial in elderly patients with unexplained anemia. BioAge is a California-based company founded in 2015 with a very direct focus on aging. It utilizes a systems biology approach and AI-based drug discovery platform to target important pathways which are found...
Justin Rebo Interview
At the Ending Age-Related Diseases 2019 Conference in New York City, we had the opportunity to interview Dr. Justin Rebo from the drug discovery biotech company BioAge. BioAge is developing a drug discovery platform that uses machine learning and artificial intelligence to discover targets that have the potential to promote healthy lifespan (healthspan) by slowing...